Inspire Medical Systems (INSP) to Release Earnings on Monday

Inspire Medical Systems (NYSE:INSP) is expected to announce its Q1 2025 earnings results after the market closes on Monday, May 5th. Analysts expect Inspire Medical Systems to post earnings of ($0.23) per share and revenue of $194.89 million for the quarter.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, analysts expect Inspire Medical Systems to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Inspire Medical Systems Price Performance

INSP stock opened at $159.89 on Friday. The stock has a market capitalization of $4.76 billion, a price-to-earnings ratio of 92.42, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39. The company has a 50-day moving average of $160.65 and a two-hundred day moving average of $179.78. Inspire Medical Systems has a 52-week low of $123.00 and a 52-week high of $257.40.

Analysts Set New Price Targets

A number of analysts have issued reports on INSP shares. Wells Fargo & Company lowered their target price on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Stifel Nicolaus lowered their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a “hold” rating on the stock in a research note on Monday, April 21st. Truist Financial cut their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. KeyCorp reduced their price target on shares of Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Finally, Piper Sandler dropped their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $218.90.

Insider Activity

In related news, CTO John Rondoni sold 583 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares of the company’s stock, valued at $1,777,187.76. The trade was a 5.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Randy Ban sold 25,584 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the sale, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by company insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.